Sibrowski W, Kühnl P, Kalmar G, Albert S, Böhm B O, Doerr H W
Abt. für Transfusionsmedizin u. Transplantationsimmunologie, Univ.-Klinik Hamburg.
Beitr Infusionsther. 1990;26:37-9.
The transfusion transmitted CMV is a possibly dangerous complication of transfusion therapy in immunodeficient patients. We therefore investigated blood donors and patients at increased risk of CMV-infection for CMV-IgG-and-IgM-antibodies. The following CMV IgG and CMV IgM prevalence rates were observed: blood donors 63.7% (0.98%), organ donors 76.9% (0%), patients on hemodialysis 83.0% (17.0%) and drug abusers 57.7% (1.3%). We conclude from our results that CMV IgG testing is useful at every blood donation to provide a large pool of CMV negative blood donors.
输血传播巨细胞病毒(CMV)是免疫缺陷患者输血治疗中一种可能危险的并发症。因此,我们对巨细胞病毒感染风险增加的献血者和患者进行了巨细胞病毒IgG和IgM抗体检测。观察到以下巨细胞病毒IgG和巨细胞病毒IgM的流行率:献血者63.7%(0.98%),器官捐献者76.9%(0%),血液透析患者83.0%(17.0%)和药物滥用者57.7%(1.3%)。我们从结果中得出结论,每次献血时进行巨细胞病毒IgG检测有助于提供大量巨细胞病毒阴性的献血者。